Clinical Trial Update: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating topotecan hydrochloride and carboplatin with or without veliparib for advanced myeloproliferative disorders and acute myeloid le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Atypical Chronic Myeloid Leukemia
• Essential Thrombocythemia
• Myelodysplastic Myeloproliferative Neoplasm
• Myelofibrosis
• Myelomonocytic Leukemia
• Polycythemia Vera

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Topotecan hydrochloride (topotecan hydrochloride)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-04-02